Prostate Cancer – Canada Drug Forecast and Market Analysis to 2023

Pages: 187 Published: April 01, 2015 Report Code: GDHC341CFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    Text to Speech

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon’s Provenge, Sanofi’s Jevtana, Johnson & Johnson’s Zytiga, Medivation/Astellas’ Xtandi, and Bayer’s Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold. In 2013, GlobalData estimated that the sales of branded prostate cancer therapies in Canada were $41m. This strong growth will be a result of the increasing incidence of prostate cancer as the population ages, increased sales resulting from the launch of eight new premium-priced pipeline products during the forecast period, and the label extension of Xtandi into the nmCRPC and hormone-sensitive prostate cancer patient populations. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Canada from 2013-2023.

Analysis of the impact of key events as well the drivers and restraints affecting Canada Prostate Cancer market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Prostate Cancer.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2013-2023 in Canada.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Staging

3.3Symptoms

3.4Prognosis

3.5Quality of Life

4Disease Management

4.1Diagnosis and Treatment Overview

4.1.1Screening and Diagnosis

4.1.2Treatment Guidelines and the Leading Prescribed Drugs

4.1.3Clinical Practice

4.2Canada

5Competitive Assessment

5.1Overview

5.2Product Profiles – Major Brands, Targeted Therapies

5.2.1Zytiga (abiraterone acetate)

5.2.2Xtandi (enzalutamide)

5.2.3Xofigo (radium 223 dichloride)

5.3Product Profiles – Major Brands, Chemotherapies

5.3.1Jevtana (cabazitaxel)

5.4Product Profiles – Major Brands, Therapeutic Vaccines

5.4.1Provenge (sipuleucel-T)

5.5Product Profiles – Major Brands, Hormone Therapies

5.5.1Zoladex (goserelin acetate)

5.5.2Lupron Depot (leuprolide acetate)

5.5.3Eligard (leuprolide acetate)

5.5.4Trelstar (triptorelin acetate)

5.5.5Firmagon (degarelix)

5.5.6Casodex (bicalutamide)

5.6Product Profiles – Major Brands, Bone Therapies

5.6.1Zometa (zoledronic acid)

5.6.2Xgeva (denosumab)

6Unmet Need and Opportunity

6.1Overview

6.2Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients

6.2.1Unmet Need

6.2.2Gap Analysis

6.2.3Opportunity

6.3Therapeutic Options for nmCRPC Patients

6.3.1Unmet Need

6.3.2Gap Analysis

6.3.3Opportunity

6.4Identification of Biomarkers to Predict Zytiga and Xtandi Resistance

6.4.1Unmet Need

6.4.2Gap Analysis

6.4.3Opportunity

6.5Defining the Best Sequence of Drugs to Manage mCRPC

6.5.1Unmet Need

6.5.2Gap Analysis

6.5.3Opportunity

7Pipeline Assessment

7.1Overview

7.2Product Profiles – Immunotherapies

7.2.1Yervoy (ipilimumab)

7.2.2ProstVac

7.2.3ProstAtak

7.2.4DCVAC/PCa

7.2.5ITK1

7.3Product Profiles – Targeted Therapies

7.3.1Custirsen Sodium

7.3.2Tasquinimod

7.3.3ARN-509

7.3.4ODM-201

8Market Outlook

8.1Canada

8.1.1Forecast

8.1.2Key Events

8.1.3Drivers and Barriers

9Appendix

9.1Bibliography

9.2Abbreviations

9.3Methodology

9.4Forecasting Methodology

9.4.1Diagnosed Prostate Cancer Patients

9.4.2Percentage Drug-Treated Patients

9.4.3Drugs Included in Each Therapeutic Class

9.4.4Launch and Patent Expiry Dates

9.4.5General Pricing Assumptions

9.4.6Individual Drug Assumptions

9.4.7Pricing of Pipeline Agents

9.5Primary Research – KOLs Interviewed for This Report

9.6Primary Research – Prescriber Survey

9.7About the Authors

9.7.1Analyst

9.7.2Director of Oncology

9.7.3Epidemiologist

9.7.4Global Head of Healthcare

9.8About GlobalData

9.9Disclaimer

List of Tables

Table 1: TNM Classification of Prostate Cancer

Table 2: Prostate Cancer Staging

Table 3: Risk-Group Classifications Used in Prostate Cancer

Table 4: Most Commonly Used Treatment Guidelines for Prostate Cancer, 2014

Table 5: Most Commonly Prescribed Hormonal Therapies for Prostate Cancer, 2014

Table 6: Most Commonly Prescribed Chemotherapeutic, Drug, and Bone Therapies for CRPC, 2014

Table 7: Diagnosis and Treatment of Prostate Cancer, Country Profile – Canada

Table 8: Leading Branded Drugs Used to Treat Prostate Cancer, 2014

Table 9: Product Profile – Zytiga

Table 10: Zytiga SWOT Analysis, 2014

Table 11: Global Sales Forecasts ($m) for Zytiga, 2013-2023

Table 12: Product Profile – Xtandi

Table 13: Xtandi SWOT Analysis, 2014

Table 14: Global Sales Forecasts ($m) for Xtandi, 2013-2023

Table 15: Product Profile – Xofigo

Table 16: Xofigo SWOT Analysis, 2014

Table 17: Global Sales Forecasts ($m) for Xofigo, 2013-2023

Table 18: Product Profile – Jevtana

Table 19: Jevtana SWOT Analysis, 2014

Table 20: Global Sales Forecasts ($m) for Jevtana, 2013-2023

Table 21: Product Profile – Provenge

Table 22: Provenge SWOT Analysis, 2014

Table 23: Global Sales Forecasts ($m) for Provenge, 2013-2023

Table 24: Product Profile – Zoladex

Table 25: Zoladex SWOT Analysis, 2014

Table 26: Product Profile – Lupron

Table 27: Lupron SWOT Analysis, 2014

Table 28: Product Profile – Eligard

Table 29: Eligard SWOT Analysis, 2014

Table 30: Product Profile – Trelstar

Table 31: Trelstar SWOT Analysis, 2014

Table 32: Product Profile – Firmagon

Table 33: Firmagon SWOT Analysis, 2014

Table 34: Product Profile – Casodex

Table 35: Casodex SWOT Analysis, 2014

Table 36: Product Profile – Zometa

Table 37: Zometa SWOT Analysis, 2014

Table 38: Product Profile – Xgeva

Table 39: Xgeva SWOT Analysis, 2014

Table 40: Unmet Need and Opportunity in Prostate Cancer

Table 41: Drugs in Phase III Clinical Trials for Prostate Cancer

Table 42: Product Profile – Yervoy

Table 43: Yervoy SWOT Analysis, 2014

Table 44: Global Sales Forecasts ($m) for Yervoy, 2013-2023

Table 45: Product Profile – ProstVac

Table 46: ProstVac SWOT Analysis, 2014

Table 47: Global Sales Forecasts ($m) for ProstVac, 2013-2023

Table 48: Product Profile – ProstAtak

Table 49: ProstAtak SWOT Analysis, 2014

Table 50: Global Sales Forecasts ($m) for ProstAtak, 2013-2023

Table 51: Product Profile – DCVAC/PCa

Table 52: DCVAC/PCa SWOT Analysis, 2014

Table 53: Global Sales Forecasts ($m) for DCVAC, 2013-2023

Table 54: Product Profile – ITK1

Table 55: ITK1 SWOT Analysis, 2014

Table 56: Global Sales Forecasts ($m) for ITK1, 2013-2023

Table 57: Product Profile – Custirsen Sodium

Table 58: Custirsen Sodium SWOT Analysis, 2014

Table 59: Global Sales Forecasts ($m) for Custirsen Sodium, 2013-2023

Table 60: Product Profile – Tasquinimod

Table 61: Tasquinimod SWOT Analysis, 2014

Table 62: Global Sales Forecasts ($m) for Tasquinimod, 2013-2023

Table 63: Product Profile – ARN-509

Table 64: ARN-509 SWOT Analysis, 2014

Table 65: Global Sales Forecasts ($m) for ARN-509, 2013-2023

Table 66: Product Profile – ODM-201

Table 67: ODM-201 SWOT Analysis, 2014

Table 68: Global Sales Forecasts ($m) for ODM-201, 2013–2023

Table 69: Sales Forecasts ($m) for Prostate Cancer in Canada, 2013-2023

Table 70: Key Events Impacting Sales for Prostate Cancer in Canada, 2013–2013

Table 71: Canada Prostate Cancer Market – Drivers and Barriers, 2013–2023

Table 72: Key Launch Dates, Marketed and Pipeline Prostate Cancer Drugs

Table 73: Key Patent Expiration or Loss of Market Exclusivity Dates, Marketed Prostate Cancer Drugs

Table 74: Average Body Weight and Surface Area Across the 9MM

Table 75: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Disease Management Flowchart for Prostate Cancer

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2013–2023

Figure 3: Yervoy’s Clinical Development

Figure 4: Potential Clinical and Commercial Positioning of Yervoy

Figure 5: ProstVac’s Clinical Development

Figure 6: Potential Clinical and Commercial Positioning of ProstVac

Figure 7: ProstAtak’s Clinical Development

Figure 8: Potential Clinical and Commercial Positioning of ProstAtak

Figure 9: DCVAC/PCa’s Clinical Development

Figure 10: Potential Clinical and Commercial Positioning of DCVAC/PCa

Figure 11: ITK1’s Clinical Development

Figure 12: Potential Clinical and Commercial Positioning of ITK1

Figure 13: Custirsen Sodium’s Clinical Development

Figure 14: Potential Clinical and Commercial Positioning of Custirsen Sodium

Figure 15: Tasquinimod’s Clinical Development

Figure 16: Potential Clinical and Commercial Positioning of Tasquinimod

Figure 17: ARN-509’s Clinical Development

Figure 18: Potential Clinical and Commercial Positioning of ARN-509

Figure 19: ODM-201’s Clinical Development

Figure 20: Potential Clinical and Commercial Positioning of ODM-201

Figure 21: Sales for Prostate Cancer in Canada by Drug Class, 2013–2023

$4995

Can be used by individual purchaser only

$14985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.